Insider Transactions in Q4 2021 at Pyxis Oncology, Inc. (PYXS)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 08
2021
|
Darren S Cline |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$90,000
$9.39 P/Share
|
|
Nov 18
2021
|
Thomas Civik |
BUY
Open market or private purchase
|
Indirect |
15,700
+50.0%
|
$188,400
$12.74 P/Share
|
|
Oct 13
2021
|
World Investments B.V. Bayer |
BUY
Conversion of derivative security
|
Direct |
2,742,338
+50.0%
|
-
|
|
Oct 13
2021
|
John L Flavin |
BUY
Conversion of derivative security
|
Direct |
2,388
+1.37%
|
-
|
|
Oct 13
2021
|
Mark Chin |
BUY
Open market or private purchase
|
Indirect |
312,500
+15.18%
|
$5,000,000
$16.0 P/Share
|
|
Oct 13
2021
|
Mark Chin |
BUY
Conversion of derivative security
|
Indirect |
1,433,261
+50.0%
|
-
|
|
Oct 13
2021
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
450,000
+28.68%
|
$7,200,000
$16.0 P/Share
|
|
Oct 13
2021
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
668,854
+50.0%
|
-
|
|
Oct 07
2021
|
Jay Feingold Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
43,750
+50.0%
|
-
|